 |
|
 |
|
|
 |
|||
       |
|||
|
|||
 |
|||
|
|||
Segment Results - 1st Quarter Fiscal Year 2011
- TECHNE Corporation and Subsidiaries
- Hematology Division
- Biotechnology Division
- R&D Systems Europe (in £'s)
- R&D Systems Europe (in $'s)
- Corporate and Other
(in thousands of $’s, except per share data)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 67,945 | 100% | 1,411 |
| Cost of sales | 15,241 | 22% | 2,340 |
| Gross margin | 52,704 | 78% | (929) |
| Gross margin percentage | 77.6% | ||
| SG&A expense | 7,552 | 11% | (486) |
| R&D expense | 6,619 | 10% | 465 |
| Amortization expense | 170 | -- | (70) |
| Interest income | (847) | (1%) | 321 |
| Other non-operating ex., net | 257 | -- | (405) |
| 13,751 | 20% | (175) | |
| Earnings before income taxes | 38,953 | 58% | (754) |
| Income taxes | 12,580 | 19% | (355) |
| 26,373 | 39% | (399) | |
| Diluted earnings per share | 0.71 | ||
| Weighted average diluted shares outstanding | 37,107 | ||
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 4,904 | 100% | 236 |
| Cost of sales | 2,509 | 51% | 190 |
| Gross margin | 2,395 | 49% | 46 |
| Gross margin percentage | 48.8% | ||
| SG&Aexpense | 328 | 7% | (42) |
| R&D expense | 198 | 4% | -- |
| Interest income | (53) | (1%) | 19 |
| 473 | 10% | (23) | |
| Pretax result | 1,922 | 39% | 69 |
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 54,141 | 100% | 2,445 |
| Intersegment sales | (7,491) | 177 | |
| 46,650 | 2,622 | ||
| Cost of sales | 11,689 | 22% | 1,804 |
| Intersegment sales | (7,578) | 20 | |
| 4,111 | 1,824 | ||
| Gross margin | 42,539 | 78% | 798 |
| Gross margin percentage | 78.4% | ||
| SG&A expense | 4,583 | 8% | (151) |
| R&D expense | 6,421 | 12% | 465 |
| Amortization expense | 170 | -- | (70) |
| Interest income | (581) | (1%) | 190 |
| Exchange loss/gain | (8) | -- | (10) |
| 10,585 | 19% | 424 | |
| Pretax result | 31,954 | 59% | 374 |
(1) Includes R&D Systems' Biotechnology Division, BiosPacific,
Inc. and R&D China
Back to Top
(in thousands of £'s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 10,571 | 100% | (310) |
| Cost of sales | 5,561 | 53% | 500 |
| Gross margin | 5,010 | 47% | (810) |
| Gross margin percentage | 47.4% | ||
| SG&A expense | 1,188 | 11% | (3) |
| Interest income | (52) | -- | 35 |
| Exchange loss/(gain) | (323) | (3%) | (234) |
| 813 | 8% | (202) | |
| Pretax result | 4,197 | 39% | (608) |
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | ||
| First Quarter | Percent Of Sales | First Quarter | |
| Sales | 16,391 | 100% | (1,447) |
| Cost of sales | 8,621 | 53% | 326 |
| Gross margin | 7,770 | 47% | (1,773) |
| Gross margin percentage | 47.4% | ||
| SG&A expense | 1,842 | 11% | (110) |
| Interest income | (81) | -- | 62 |
| Exchange loss | (497) | (3%) | (352) |
| 1,264 | 8% | (400) | |
| Pretax result | 6,506 | 39% | (1,373) |
Back to Top
(in thousands of $’s)
| Fiscal 2011 | Increase (Decrease) From Fiscal 2010 | |
| First Quarter | First Quarter | |
| Interest income | 132 | (50) |
| Rental income | 123 | 42 |
| 255 | (8) | |
| SG&A expense | 799 | (183) |
| Other-Building expenses | 556 | 8 |
| Other-Equity Investment losses | 329 | (9) |
| 1,684 | (184) | |
| Pretax result | (1,429) | 176 |
Back to Top
(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC
|
Home -
Company News -
Financial Information -
About TECHNE -
Map/Directions -
Products -
Contact Us
TECHNE CORPORATION 614 McKinley Place N.E. Minneapolis, MN 55413-2610 Phone: (612)379-8854 Fax: (612)379-6580 e-mail: techinfo@techne-corp.com * Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote. Quote provided by Barchart.com. |